Literature DB >> 23413031

Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis.

Signe Ingvarsen1, Astrid Porse, Charlotte Erpicum, Ludovic Maertens, Henrik J Jürgensen, Daniel H Madsen, Maria C Melander, Henrik Gårdsvoll, Gunilla Høyer-Hansen, Agnès Noel, Kenn Holmbeck, Lars H Engelholm, Niels Behrendt.   

Abstract

The group of matrix metalloproteases (MMPs) is responsible for multiple processes of extracellular matrix remodeling in the healthy body but also for matrix and tissue destruction during cancer invasion and metastasis. The understanding of the contributions from each individual MMP, both in healthy and pathological events, has been complicated by the lack of specific inhibitors and the fact that some of the potent MMPs are multifunctional enzymes. These factors have also hampered the setup of therapeutic strategies targeting MMP activity. A tempting target is the membrane-associated MT1-MMP, which has well-documented importance in matrix degradation but which takes part in more than one pathway in this regard. In this report, we describe the selective targeting of a single function of this enzyme by means of a specific monoclonal antibody against MT1-MMP, raised in an MT1-MMP knock-out mouse. The antibody blocks the enzyme ability to activate proMMP-2 without interfering with the collagenolytic function or the general proteolytic activity of MT1-MMP. Using this antibody, we have shown that the MT1-MMP-catalyzed activation of proMMP-2 is involved in the outgrowth of cultured lymphatic endothelial cells in a collagen matrix in vitro, as well as in lymphatic vessel sprouting assayed ex vivo. This is the first example of the complete inactivation of a single function of a multifunctional MMP and the use of this strategy to pursue its role.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23413031      PMCID: PMC3624404          DOI: 10.1074/jbc.M112.447169

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris.

Authors:  Magnus Kjaergaard; Henrik Gårdsvoll; Daniel Hirschberg; Steen Nielbo; Anand Mayasundari; Cynthia B Peterson; Anna Jansson; Thomas J D Jørgensen; Flemming M Poulsen; Michael Ploug
Journal:  Protein Sci       Date:  2007-09       Impact factor: 6.725

2.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

3.  The non-phagocytic route of collagen uptake: a distinct degradation pathway.

Authors:  Daniel H Madsen; Signe Ingvarsen; Henrik J Jürgensen; Maria C Melander; Lars Kjøller; Amanda Moyer; Christian Honoré; Charlotte A Madsen; Peter Garred; Sven Burgdorf; Thomas H Bugge; Niels Behrendt; Lars H Engelholm
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

4.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas.

Authors:  A Okada; J P Bellocq; N Rouyer; M P Chenard; M C Rio; P Chambon; P Basset
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells.

Authors:  Signe Ingvarsen; Daniel H Madsen; Thore Hillig; Leif R Lund; Kenn Holmbeck; Niels Behrendt; Lars H Engelholm
Journal:  Biol Chem       Date:  2008-07       Impact factor: 3.915

6.  Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2.

Authors:  A Y Strongin; B L Marmer; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1993-07-05       Impact factor: 5.157

7.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.

Authors:  H Nakamura; H Ueno; K Yamashita; T Shimada; E Yamamoto; M Noguchi; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

8.  Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2.

Authors:  Jing-Mei Su; Yu-Quan Wei; Ling Tian; Xia Zhao; Li Yang; Qiu-Ming He; Yu Wang; You Lu; Yang Wu; Fen Liu; Ji-Yan Liu; Jin-Liang Yang; Yan-Yan Lou; Bing Hu; Ting Niu; Yan-Jun Wen; Fei Xiao; Hong-Xin Deng; Jiong Li; Bing Kan
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Authors:  B Basu; P Correa de Sampaio; H Mohammed; M Fogarasi; P Corrie; N A Watkins; P A Smethurst; W R English; W H Ouwehand; G Murphy
Journal:  Int J Biochem Cell Biol       Date:  2011-11-26       Impact factor: 5.085

10.  Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP.

Authors:  Farideh Sabeh; Ichiro Ota; Kenn Holmbeck; Henning Birkedal-Hansen; Paul Soloway; Milagros Balbin; Carlos Lopez-Otin; Steven Shapiro; Masaki Inada; Stephen Krane; Edward Allen; Duane Chung; Stephen J Weiss
Journal:  J Cell Biol       Date:  2004-11-22       Impact factor: 10.539

View more
  26 in total

1.  [Changes of lymphatic vessel density in lung adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma and the regulatory factors].

Authors:  Ping He; Xia Gu; Xin Zeng; Yongmei Zheng; Xiaodong Lin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

3.  Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells.

Authors:  Alain Zgheib; Sylvie Lamy; Borhane Annabi
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

Review 4.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

5.  Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain.

Authors:  Sanghyun Hong; Albert G Remacle; Sergei A Shiryaev; Wonjun Choi; Swathi K Hullugundi; Jennifer Dolkas; Mila Angert; Tasuku Nishihara; Tony L Yaksh; Alex Y Strongin; Veronica I Shubayev
Journal:  Brain Behav Immun       Date:  2016-11-07       Impact factor: 7.217

Review 6.  Matrix metalloproteinase 14 modulates signal transduction and angiogenesis in the cornea.

Authors:  Jin-Hong Chang; Yu-Hui Huang; Christy M Cunningham; Kyu-Yeon Han; Michael Chang; Motoharu Seiki; Zhongjun Zhou; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2015-12-02       Impact factor: 6.048

Review 7.  Matrix metalloproteinases as breast cancer drivers and therapeutic targets.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  Front Biosci (Landmark Ed)       Date:  2015-06-01

8.  MT-LOOP-dependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion.

Authors:  Anna M Woskowicz; Sarah A Weaver; Yasuyuki Shitomi; Noriko Ito; Yoshifumi Itoh
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

Review 9.  New strategies for targeting matrix metalloproteinases.

Authors:  Gregg B Fields
Journal:  Matrix Biol       Date:  2015-01-14       Impact factor: 11.583

10.  Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.

Authors:  Sonia Pahwa; Maciej J Stawikowski; Gregg B Fields
Journal:  Cancers (Basel)       Date:  2014-02-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.